PE20171107A1 - Anticuerpos mejorados contra il-6 - Google Patents
Anticuerpos mejorados contra il-6Info
- Publication number
- PE20171107A1 PE20171107A1 PE2017000804A PE2017000804A PE20171107A1 PE 20171107 A1 PE20171107 A1 PE 20171107A1 PE 2017000804 A PE2017000804 A PE 2017000804A PE 2017000804 A PE2017000804 A PE 2017000804A PE 20171107 A1 PE20171107 A1 PE 20171107A1
- Authority
- PE
- Peru
- Prior art keywords
- amino acid
- acid sequence
- sequence seq
- cdr1
- cdr2
- Prior art date
Links
- 108090001005 Interleukin-6 Proteins 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011190 diabetic macular edema Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se refiere a un anticuerpo o fragmento de union al antigeno que comprende: una region variable de cadena pesada caracterizada porque comprende una CDR1 con una secuencia de aminoacidos SEC ID NO: 45, entre otros; una CDR2 con una secuencia de aminoacidos SEC ID NO: 46, entre otros; y una CDR3 con una secuencia de aminoacidos SEC ID NO: 33, entre otros; y una region variable de cadena ligera caracterizada porque comprende una CDR1 con una secuencia de aminoacidos SEQ ID NO: 34; una CDR2 con una secuencia de aminoacidos SEC ID NO: 35; y una CDR3 con una secuencia de aminoacidos SEC ID NO: 36. Tambien se refiere a una composicion farmaceutica, a un acido nucleico, a un vector de transferencia y a una celula hospedera. Dicho anticuerpo es especifico contra la glucoproteina IL-6, siendo util en el tratamiento de retinopatia diabetica, edema macular diabetico, entre otros.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077105P | 2014-11-07 | 2014-11-07 | |
| US201462087448P | 2014-12-04 | 2014-12-04 | |
| US201562247705P | 2015-10-28 | 2015-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171107A1 true PE20171107A1 (es) | 2017-08-07 |
Family
ID=54602042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000804A PE20171107A1 (es) | 2014-11-07 | 2015-11-06 | Anticuerpos mejorados contra il-6 |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US11142571B2 (es) |
| EP (3) | EP3632931A1 (es) |
| JP (1) | JP6594438B2 (es) |
| KR (2) | KR102636726B1 (es) |
| CN (1) | CN107249631B (es) |
| AU (1) | AU2015342882B2 (es) |
| CA (1) | CA2965689C (es) |
| CL (1) | CL2017001135A1 (es) |
| CO (1) | CO2017005404A2 (es) |
| CR (1) | CR20170231A (es) |
| DK (2) | DK4268843T3 (es) |
| EA (1) | EA035199B1 (es) |
| ES (1) | ES2756275T3 (es) |
| FI (1) | FI4268843T3 (es) |
| HR (1) | HRP20191945T1 (es) |
| HU (1) | HUE046181T2 (es) |
| IL (1) | IL251858B (es) |
| LT (1) | LT4268843T (es) |
| MA (1) | MA51554A (es) |
| MX (2) | MX385206B (es) |
| MY (1) | MY185114A (es) |
| PE (1) | PE20171107A1 (es) |
| PH (1) | PH12017500809B1 (es) |
| PL (1) | PL3215530T3 (es) |
| PT (2) | PT3215530T (es) |
| RS (1) | RS59805B1 (es) |
| SA (1) | SA517381458B1 (es) |
| SG (2) | SG10202103420PA (es) |
| SI (1) | SI3215530T1 (es) |
| UA (1) | UA122673C2 (es) |
| WO (1) | WO2016073890A1 (es) |
| ZA (1) | ZA201702985B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3353203A2 (en) | 2015-09-23 | 2018-08-01 | H. Hoffnabb-La Roche Ag | Optimized variants of anti-vegf antibodies |
| AR107708A1 (es) * | 2016-02-23 | 2018-05-23 | Eleven Biotherapeutics Inc | Formulaciones de antagonista de il-6 y sus usos |
| MX2019007144A (es) * | 2016-12-19 | 2019-10-07 | Glenmark Pharmaceuticals Sa | Nuevos agonistas de tnfr y sus usos. |
| JP7216006B2 (ja) | 2017-03-22 | 2023-01-31 | ジェネンテック， インコーポレイテッド | ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法 |
| UA129242C2 (uk) | 2017-03-22 | 2025-02-26 | Дженентек, Інк. | Оптимізована композиція антитіла для лікування захворювань очей |
| CN109867723B (zh) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
| PE20230252A1 (es) | 2020-03-13 | 2023-02-07 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos de estos |
| BR112022018847A2 (pt) | 2020-03-24 | 2022-11-22 | Genentech Inc | Anticorpos, ácido nucleico, célula hospedeira, conjugados, composição farmacêutica, dispositivo de entrega de ação prolongada para entrega ocular, método para tratar um distúrbio e uso do anticorpo |
| EP4228706A1 (en) | 2020-10-15 | 2023-08-23 | Genentech, Inc. | Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics |
| CN116554298A (zh) * | 2022-02-25 | 2023-08-08 | 南京工业大学 | 一种强化细菌卷曲菌毛提高人表皮生长因子分泌生产效率的方法 |
| CN115343483B (zh) * | 2022-08-12 | 2024-11-26 | 苏州邦器生物技术有限公司 | 一种自身免疫性糖尿病检测用试剂盒及其制备方法 |
| CN120112551A (zh) * | 2022-10-24 | 2025-06-06 | 豪夫迈·罗氏有限公司 | 预测对il-6拮抗剂的反应 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| WO1992015677A1 (en) | 1991-03-01 | 1992-09-17 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| EP0580737B1 (en) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
| TW311927B (es) | 1995-07-11 | 1997-08-01 | Minnesota Mining & Mfg | |
| EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
| US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
| EP1137941B2 (en) | 1998-12-10 | 2013-09-11 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| CA2381770C (en) | 1999-08-24 | 2007-08-07 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| EP1354034B8 (en) | 2000-11-30 | 2008-06-18 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| AU2003234439A1 (en) | 2002-05-07 | 2003-11-11 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| JP2006516957A (ja) * | 2002-11-15 | 2006-07-13 | セントカー・インコーポレーテツド | Ｉｌ−６アンタゴニストの抗血管形成用途 |
| BRPI0417270A (pt) | 2003-12-23 | 2007-03-27 | Rinat Neuroscience Corp | anticorpos agonistas antitrkc e métodos para utilização dos mesmos |
| EA012464B1 (ru) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Антитело против cd20 и его применение |
| MX2007002856A (es) | 2004-09-02 | 2007-09-25 | Genentech Inc | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2635615A1 (en) | 2005-12-30 | 2007-07-12 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| JP2009529339A (ja) | 2006-03-13 | 2009-08-20 | アブリンクス エン．ヴェー． | Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド |
| EP2021463B1 (en) | 2006-05-19 | 2016-11-23 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
| ES2721753T3 (es) * | 2007-05-21 | 2019-08-05 | Alderbio Holdings Llc | Anticuerpos contra IL-6 y usos de los mismos |
| MX2010002815A (es) | 2007-09-14 | 2010-07-30 | Sanofi Pasteur Biologics Co | Composiciones farmaceuticas que contienen toxoides a y b de clostridium difficile. |
| US8043620B2 (en) | 2007-11-21 | 2011-10-25 | Amgen Inc. | Wise binding agents and epitopes |
| US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
| MX2010007728A (es) | 2008-01-15 | 2010-12-21 | Abbott Gmbh & Co Kg | Composiciones proteinicas en polvo y metodos para elaborar las mismas. |
| HRP20150799T1 (hr) | 2008-08-05 | 2015-09-11 | Novartis Ag | Sastavi i postupci za protutijela protiv komplementnog proteina c5 |
| WO2010029748A1 (ja) | 2008-09-12 | 2010-03-18 | 有限会社眞友商会 | 噴水装置 |
| WO2010039750A2 (en) | 2008-10-01 | 2010-04-08 | Monsanto Technology Llc | Transgenic plants with enhanced agronomic traits |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| BRPI0921319A2 (pt) | 2008-11-26 | 2018-10-16 | Glaxo Group Ltd | composição, método para dispensação de uma composição, e para tratar, prevenir ou diagnosticar uma condição ocular, e, processo para produzir uma composição farmacêutica |
| BRPI1007005A2 (pt) | 2009-01-29 | 2016-03-22 | Medimmune Llc | anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| EP2593142B8 (en) | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
| RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| HK1214499A1 (zh) | 2012-10-25 | 2016-07-29 | Medimmune, Llc | 穩定的低粘度抗體配製品 |
| AU2013342163B2 (en) | 2012-11-08 | 2018-08-16 | F. Hoffmann-La Roche Ltd | IL-6 antagonists and uses thereof |
| AU2014286996A1 (en) | 2013-07-12 | 2016-01-07 | Iveric Bio, Inc. | Methods for treating or preventing ophthalmological conditions |
| WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2015
- 2015-11-06 ES ES15797538T patent/ES2756275T3/es active Active
- 2015-11-06 LT LTEP23189385.0T patent/LT4268843T/lt unknown
- 2015-11-06 JP JP2017543332A patent/JP6594438B2/ja active Active
- 2015-11-06 HR HRP20191945TT patent/HRP20191945T1/hr unknown
- 2015-11-06 CR CR20170231A patent/CR20170231A/es unknown
- 2015-11-06 WO PCT/US2015/059532 patent/WO2016073890A1/en not_active Ceased
- 2015-11-06 SG SG10202103420PA patent/SG10202103420PA/en unknown
- 2015-11-06 MA MA051554A patent/MA51554A/fr unknown
- 2015-11-06 DK DK23189385.0T patent/DK4268843T3/da active
- 2015-11-06 PE PE2017000804A patent/PE20171107A1/es unknown
- 2015-11-06 AU AU2015342882A patent/AU2015342882B2/en active Active
- 2015-11-06 FI FIEP23189385.0T patent/FI4268843T3/fi active
- 2015-11-06 CA CA2965689A patent/CA2965689C/en active Active
- 2015-11-06 EA EA201791005A patent/EA035199B1/ru not_active IP Right Cessation
- 2015-11-06 SG SG11201703574VA patent/SG11201703574VA/en unknown
- 2015-11-06 CN CN201580065652.6A patent/CN107249631B/zh active Active
- 2015-11-06 EP EP19189890.7A patent/EP3632931A1/en active Pending
- 2015-11-06 UA UAA201705592A patent/UA122673C2/uk unknown
- 2015-11-06 PT PT157975384T patent/PT3215530T/pt unknown
- 2015-11-06 MX MX2017005992A patent/MX385206B/es unknown
- 2015-11-06 PH PH1/2017/500809A patent/PH12017500809B1/en unknown
- 2015-11-06 EP EP15797538.4A patent/EP3215530B9/en active Active
- 2015-11-06 RS RS20191447A patent/RS59805B1/sr unknown
- 2015-11-06 PL PL15797538T patent/PL3215530T3/pl unknown
- 2015-11-06 IL IL251858A patent/IL251858B/en unknown
- 2015-11-06 DK DK15797538T patent/DK3215530T3/da active
- 2015-11-06 KR KR1020177014412A patent/KR102636726B1/ko active Active
- 2015-11-06 US US15/524,727 patent/US11142571B2/en active Active
- 2015-11-06 EP EP23189385.0A patent/EP4268843B1/en active Active
- 2015-11-06 MY MYPI2017000609A patent/MY185114A/en unknown
- 2015-11-06 HU HUE15797538A patent/HUE046181T2/hu unknown
- 2015-11-06 SI SI201530995T patent/SI3215530T1/sl unknown
- 2015-11-06 KR KR1020247004699A patent/KR102770849B1/ko active Active
- 2015-11-06 PT PT231893850T patent/PT4268843T/pt unknown
-
2017
- 2017-04-28 ZA ZA201702985A patent/ZA201702985B/en unknown
- 2017-05-03 SA SA517381458A patent/SA517381458B1/ar unknown
- 2017-05-05 CL CL2017001135A patent/CL2017001135A1/es unknown
- 2017-05-08 MX MX2021008663A patent/MX2021008663A/es unknown
- 2017-05-30 CO CONC2017/0005404A patent/CO2017005404A2/es unknown
-
2021
- 2021-09-13 US US17/473,696 patent/US20220169719A1/en not_active Abandoned
-
2024
- 2024-05-13 US US18/662,445 patent/US20250059270A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171107A1 (es) | Anticuerpos mejorados contra il-6 | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| AR085383A1 (es) | Anticuerpos contra el il33r humano y usos de los mismos | |
| PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20141188A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20170289A1 (es) | Anticuerpos anti tigit | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos |